| Tumour exosomal CEMIP protein promotes cancer cell colonization in brain metastasis G Rodrigues, A Hoshino, CM Kenific, IR Matei, L Steiner, D Freitas, ... Nature cell biology 21 (11), 1403-1412, 2019 | 310 | 2019 |
| Identification of miR-187 and miR-182 as biomarkers of early diagnosis and prognosis in patients with prostate cancer treated with radical prostatectomy I Casanova-Salas, J Rubio-Briones, A Calatrava, C Mancarella, E Masiá, ... The Journal of urology 192 (1), 252-259, 2014 | 142 | 2014 |
| Advanced prostate cancer with ATM loss: PARP and ATR inhibitors A Neeb, N Herranz, S Arce-Gallego, S Miranda, L Buroni, W Yuan, A Athie, ... European urology 79 (2), 200-211, 2021 | 85 | 2021 |
| Mitochondrial Complex I Inhibitors Expose a Vulnerability for Selective Killing of Pten-Null Cells. TLC aguib A, Mathew G, Reczek CR, Watrud K, Ambrico A, Herzka T, Salas IC ... Cell Reports 23 (1), 58-67, 2018 | 81 | 2018 |
| miRNAs as biomarkers in prostate cancer I Casanova-Salas, J Rubio-Briones, A Fernández-Serra, ... Clinical and Translational Oncology 14, 803-811, 2012 | 68 | 2012 |
| Clinico-pathological significance of the molecular alterations of the SPOP gene in prostate cancer M García-Flores, I Casanova-Salas, J Rubio-Briones, A Calatrava, ... European journal of cancer 50 (17), 2994-3002, 2014 | 67 | 2014 |
| MiR-187 targets the androgen-regulated gene ALDH1A3 in prostate cancer I Casanova-Salas, E Masia, A Arminan, A Calatrava, C Mancarella, ... PloS one 10 (5), e0125576, 2015 | 63 | 2015 |
| Quantitative and qualitative analysis of blood-based liquid biopsies to inform clinical decision-making in prostate cancer I Casanova-Salas, A Athie, PC Boutros, M Del Re, DT Miyamoto, ... European urology 79 (6), 762-771, 2021 | 60 | 2021 |
| The PHLPP2 phosphatase is a druggable driver of prostate cancer progression DG Nowak, KC Katsenelson, KE Watrud, M Chen, G Mathew, ... Journal of Cell Biology 218 (6), 1943-1957, 2019 | 34 | 2019 |
| ERG deregulation induces IGF-1R expression in prostate cancer cells and affects sensitivity to anti-IGF-1R agents C Mancarella, I Casanova-Salas, A Calatrava, S Ventura, C Garofalo, ... Oncotarget 6 (18), 16611, 2015 | 26 | 2015 |
| Optimizing the clinical utility of PCA3 to diagnose prostate cancer in initial prostate biopsy J Rubio-Briones, A Borque, LM Esteban, J Casanova, A Fernandez-Serra, ... BMC cancer 15, 1-8, 2015 | 18 | 2015 |
| Optimizing prostate cancer screening; prospective randomized controlled study of the role of PSA and PCA3 testing in a sequential manner in an opportunistic screening program J Rubio-Briones, J Casanova, R Dumont, L Rubio, A Fernandez-Serra, ... Actas Urológicas Españolas (English Edition) 38 (4), 217-223, 2014 | 15 | 2014 |
| Insulin-like growth factor 1 receptor affects the survival of primary prostate cancer patients depending on TMPRSS2-ERG status C Mancarella, I Casanova-Salas, A Calatrava, M García-Flores, ... BMC cancer 17, 1-12, 2017 | 13 | 2017 |
| External validation of FXYD3 and KRT20 as predictive biomarkers for the presence of micrometastasis in muscle invasive bladder cancer lymph nodes M Ramírez-Backhaus, A Fernández-Serra, J Rubio-Briones, PC Garcia, ... Actas Urológicas Españolas (English Edition) 39 (8), 473-481, 2015 | 12 | 2015 |
| Genomic biomarkers and genome-wide loss-of-heterozygosity scores in metastatic prostate cancer following progression on androgen-targeting therapies AJ Zurita, RP Graf, G Villacampa, K Raskina, E Sokol, D Jin, ... JCO Precision Oncology 6, e2200195, 2022 | 11 | 2022 |
| Update on the diagnosis of PCa in urine. The current role of urine markers A Fernandez-Serra, I Casanova-Salas, L Rubio, A Calatrava, ... Archivos Espanoles de Urologia 68 (3), 240-249, 2015 | 11 | 2015 |
| Diffusion MRI signal cumulants and hepatocyte microstructure at fixed diffusion time: Insights from simulations, 9.4 T imaging, and histology F Grussu, K Bernatowicz, I Casanova‐Salas, N Castro, P Nuciforo, ... Magnetic Resonance in Medicine 88 (1), 365-379, 2022 | 3 | 2022 |
| Genomic evolution from hormonal therapies and suitability of prostate cancer diagnostic specimens for metastatic prostate cancer (mPC) genomic stratification. AJ Zurita, R Graf, G Villacampa, K Raskina, E Sokol, DX Jin, RSP Huang, ... Journal of Clinical Oncology 40 (6_suppl), 143-143, 2022 | 2 | 2022 |
| 315 prospective randomized controlled study of the role of PSA and PCA3 testing in a sequential manner in an opportunistic screening program for early diagnosis of prostate cancer J Rubio-Briones, J Casanova, R Dumont, L Rubio, A Fernandez-Serra, ... European Urology Supplements 2 (14), e315, 2015 | 2 | 2015 |
| A randomized phase 2 trial to evaluate the antitumor activity of enzalutamide (EZ) and talazoparib (TALA) for the treatment of metastatic hormone-naïve prostate cancer (mHNPC … J Mateo, Á Borque, DE Castellano, E Castro, MAA Climent Duran, A Font, ... Journal of Clinical Oncology 40 (6_suppl), TPS209-TPS209, 2022 | 1 | 2022 |
